Envoy Medical, Inc.

What they do

Envoy Medical designs and develops fully implanted hearing solutions, including the investigational Acclaim cochlear implant, which has Breakthrough Device designation from the FDA. The company is pursuing a Modular PMA pathway and has submitted the first of four modules. Its operations are primarily R&D-focused, with minimal revenue from sales or services.

Revenue drivers

• Investigation device sales/services — Quarterly revenue is minimal, e.g., $51,000 in Q2 2026, and appears to come from limited product sales or services, not a commercial launch.

Recent performance

For Q2 2026, Envoy reported net revenue of $51,000, with cost of goods sold of $278,000, a net loss of $23.8 million for 2025, and negative operating cash flow of $18.2 million in 2025. As of June 30, 2026, the company had $19.7 million in cash and equivalents, total assets of $23.9 million, and shareholder equity of $3.3 million. R&D expenses increased 26% year-over-year to $3.1 million in Q2 2026, reflecting clinical trial and PMA activity.

Strategy

Management's stated strategy is to bring the fully implanted Acclaim cochlear implant to market by completing the Modular PMA submission, with the final module targeted for Q2 2027. They are executing a pivotal clinical trial, with positive 12-month data reported in August 2026. The company is expanding its intellectual property portfolio internationally and laying operational groundwork to support future demand.

Risks

• Regulatory approval risk — The company is dependent on FDA approval of the Acclaim implant through the Modular PMA pathway; failure to obtain approval would prevent commercialization.
• Clinical trial failure risk — The pivotal trial's primary efficacy endpoint is based on 12-month data; unfavorable results could delay or prevent approval.
• Cash runway risk — With only $19.7 million cash and ongoing operating losses, the company may need additional capital; termination of the ATM facility limits one funding source.
• Delisting risk — The company received a delisting notice from Nasdaq in May 2026, which could impact stock liquidity and investor confidence.

Outlook

Management expects to submit the remaining three modules of the Modular PMA application on a rolling basis, with the final module containing clinical data targeted for Q2 2027. They anticipate continued clinical trial follow-up and regulatory engagement, and they are positioning for a commercial launch if approved. The company also highlighted positive 12-month speech perception data, showing a 38.0 percentage point improvement from baseline.